Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multitracer PET and Advanced MRI Metabolic Profiling of Glioblastoma
NCT06613841Phase 1Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- May 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluciclovine f 18 in glioblastoma (GBM), sponsored by Abramson Cancer Center. Primary endpoint: Standardized Uptake Value at 2 years. Started May 2025; status: recruiting.
02
Drugs
fluciclovine f 18
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06613841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613841.